Lenvatinib and Pembrolizumab Combination Therapy In HPV-associated Recurrent Respiratory Papilloma Patients With Laryngeal, Tracheal, and/or Pulmonary Involvement
Conditions: Human Papilloma Virus; Recurrent Respiratory Papillomatosis Interventions: Drug: Lenvatinib; Drug: Pembrolizumab Sponsors: Massachusetts General Hospital; Eisai Inc.; Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials